Microbot Medical surges as robotic system delivers in pre-clinical study
22/05/2023 15:31
** Shares of Microbot Medical Inc MBOT.O up 55% at $1.9
** Co says Liberty, its surgical robotic system, achieved
100% success rate in pre-clinical animal study by European
physicians
** Liberty is the first ever fully disposable surgical robot
designed to streamline endovascular procedures, according to the
co's website
** The system was found intuitive, easy to set up and use -
MBOT
** Co plans to enter human trial phase in H2
** Co plans on performing pre-clinical studies in the U.S.
and other target markets
** Separately, co disclosed deals with certain executive
officers for 30%-40% reduction of base salary
** More than 33 mln shares traded, 580 times their 50-day
moving avg
** Stock down 36% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))
Recent news on Microbot Medical
See all newsBrief: Microbot Medical® Enters Into An Agreement To Expand Access For America’S Veteran And Military Patient Populations
Microbot Medical rises as U.S. federal supply deal expands reach of robotic surgical device
Brief: Microbot Medical Recorded Revenue During Its Quarter Ended March 31, Benefiting From Limited Market Release Of Liberty System
Brief: Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites
Brief: Microbot Medical Continues Its 2025 Momentum Announces Key 2026 Milestones